SVA merger forms BetaNova for type 1 diabetes trials
BetaNova Biotherapeutics was created via a merger, combining cell therapy, gene-editing and implantable device technologies for functional-cure efforts in type 1 diabetes, with an equal partnership structure and $10M convertible note financing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.